Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Manganous chloride anhydrous

Related Products

Hot Products

Name

Manganous chloride anhydrous

EINECS 231-869-6
CAS No. 7773-01-5 Density 2.98 g/cm3
PSA 0.00000 LogP -5.99200
Solubility 723 g/L (25 °C) in water Melting Point 652 °C(lit.)
Formula MnCl2 Boiling Point 1225 °C
Molecular Weight 125.844 Flash Point 1190°C
Transport Information UN 3288 6.1/PG 3 Appearance Rose red crystalline powder
Safety 45-61-22-36 Risk Codes 22-52-48/22-25
Molecular Structure Molecular Structure of 7773-01-5 (Manganese chloride) Hazard Symbols HarmfulXn
Synonyms

Manganese chloride;CCRIS 6882;HSDB 2154;Manganese bichloride;Manganese dichloride;Manganous chloride;NSC 9879;Scacchite;UNII-6YB4901Y90;

Article Data 161

Manganous chloride anhydrous Specification

Manganous chloride anhydrous is also called as Manganese dichloride with the chemical formula MnCl2. The substance has the CAS register number 7773-01-5 and the EINECS number 231-869-6. It is soluble in water but moisture sensitive, which is hygroscopic. In addition, Manganous chloride anhydrous is incompatible with strong acids, reactive metals, hydrogen peroxide. This chemical is rose red crystalline powder. Manganism, or manganese poisoning, can be caused by long-term exposure to manganese dust or fumes.

Properties: Manganous chloride anhydrous is a polymeric solid, which adopts a layered cadmium chloride-like structure. Upon treatment with typical organic ligands, manganese(II) undergoes oxidation by air to give Mn(III) complexes. Examples include [Mn(EDTA)]-, [Mn(CN)6]3-, and [Mn(acetylacetonate)3]. Triphenylphosphine forms a labile 2:1 adduct:

MnCl2 + 2 Ph3P → [MnCl2(Ph3P)2]

Manganous chloride anhydrous is a weak Lewis acid, reacting with chloride ions to produce a series of solids containing the following ions [MnCl3]-, [MnCl4]2-, and [MnCl6]4-. Both [MnCl3]- and [MnCl4]2- are polymeric. Manganous chloride anhydrous serves as a starting point for the synthesis of a variety of manganese compounds. For example, manganocene is prepared by reaction of MnCl2 with a solution of sodium cyclopentadienide in THF.

MnCl2 + 2 NaC5H5 → Mn(C5H5)2 + 2 NaCl

Preparation: Manganous chloride anhydrous can be prepared by manganese metal or manganese(II) carbonate and hydrochloric acid in the laboratory:

Mn + 2 HCl → MnCl2 + H2
MnCO3 + 2 HCl → MnCl2 + H2O + CO2

Moreover, it can also be produced by pyrolusite restored by pulverized coal to give manganous oxide or directly by manganese ore, and then reacts with concentrated hydrochloric acid. After that, via filtration, impurity removing, concentration, crystallization and centrifugal separation, you can get the end product of Manganous chloride.

MnO2 + C → MnO + CO
MnO2 + CO → MnO + CO2
MnO + 2 HCl → MnCl2 + H2O
MnO2 + 2 HCl → MnCl2 + 2 H2O + Cl2

Uses: Manganous chloride is the precursor to the antiknock compound methylcyclopentadienyl manganese tricarbonyl. The main application is used in the production of dry cell batteries. Manganous chloride anhydrous is also used in 31P-NMR to determine the size and lamellarity of phospholipid vesicles. Manganous chloride can be used as conductive salt in electroplating. Meanwhile, it is used as antioxidants which can restrain the oxidation of ferrous.

When you are using Manganous chloride anhydrous, please be cautious about it. It is harmful and toxic if swallowed. In addition, it is harmful to aquatic organisms. There will be a danger of serious damage to health by prolonged exposure if swallowed. When using it, you should wear suitable protective clothing. In case of accident or if you feel unwell, you can seek medical advice immediately. Finally, you must avoid release to the environment.

You can still convert the following datas into molecular structure of Manganous chloride anhydrous:
(1)Canonical SMILES: Cl[Mn]Cl
(2)InChI: InChI=1S/2ClH.Mn/h2*1H;/q;;+2/p-2
(3)InChIKey: GLFNIEUTAYBVOC-UHFFFAOYSA-L

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LDLo unreported 4mg/kg (4mg/kg)   Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929.
dog LD50 intravenous 202mg/kg (202mg/kg)   Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
dog LDLo parenteral 128mg/kg (128mg/kg) CARDIAC: OTHER CHANGES

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

GASTROINTESTINAL: OTHER CHANGES
Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929.
dog LDLo unreported 600ug/kg (0.6mg/kg)   Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929.
guinea pig LD50 oral 916mg/kg (916mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 36(9), Pg. 15, 1971.
guinea pig LDLo subcutaneous 180mg/kg (180mg/kg)   Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
guinea pig LDLo unreported 60mg/kg (60mg/kg)   Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929.
mouse LD50 intramuscular 255mg/kg (255mg/kg)   Russian Pharmacology and Toxicology Vol. 38, Pg. 221, 1975.
mouse LD50 intraperitoneal 121mg/kg (121mg/kg)   Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 244, Pg. 17, 1962.
mouse LD50 intravenous 38mg/kg (38mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION

BEHAVIORAL: ATAXIA
Acta Radiologica. Vol. 38, Pg. 770, 1997.
mouse LD50 oral 1031mg/kg (1031mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 36(9), Pg. 15, 1971.
mouse LDLo subcutaneous 210mg/kg (210mg/kg)   Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
rabbit LDLo intravenous 64800ug/kg (64.8mg/kg)   Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
rabbit LDLo parenteral 41mg/kg (41mg/kg) CARDIAC: OTHER CHANGES

GASTROINTESTINAL: OTHER CHANGES

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929.
rabbit LDLo subcutaneous 180mg/kg (180mg/kg)   Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
rabbit LDLo unreported 6500ug/kg (6.5mg/kg)   Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929.
rat LD50 intramuscular 700mg/kg (700mg/kg)   Russian Pharmacology and Toxicology Vol. 38, Pg. 221, 1975.
rat LD50 intraperitoneal 147mg/kg (147mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Indian Journal of Pharmacology. Vol. 23, Pg. 153, 1991.
rat LD50 intravenous 92600ug/kg (92.6mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Indian Journal of Pharmacology. Vol. 23, Pg. 153, 1991.
rat LD50 oral 250mg/kg (250mg/kg)   Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 26(12), Pg. 8, 1961.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 7773-01-5